SCHEMBL2865775

SCHEMBL2865775

Nc1ncc2c(n1)-c1ocnc1CC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.50
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
POLB P06746 1/20 0.47
CCNA2 P20248 4/20 0.42
CDK2 P24941 4/20 0.42
HTT P42858 3/20 0.40
MAPT P10636 2/20 0.40
PIK3CD O00329 1/20 0.36
PIK3R1 P27986 1/20 0.36
MAP3K14 Q99558 5/20 0.36
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34
HPGD P15428 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PIKFYVE Q9Y2I7 3/20 0.34
FGFR1 P11362 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2873139 0.69 KDM4E (0.49) HSP90AA1KDM4EALDH1A1POLBCCNA2
SCHEMBL2874734 0.68 ALDH1A1 (0.47) HSP90AA1KDM4EALDH1A1POLBCCNA2
SCHEMBL4516423 0.68 CDK2 (0.60) HSP90AA1KDM4EALDH1A1POLBCCNA2
SCHEMBL24329228 0.66 KDM4E (0.45) HSP90AA1KDM4EALDH1A1POLBCCNA2
SCHEMBL1531483 0.66 CDK2 (0.57) HSP90AA1KDM4EALDH1A1POLBCCNA2
SCHEMBL4990063 0.65 KDM4E (1.00) HSP90AA1KDM4EALDH1A1POLBCCNA2
SCHEMBL24328556 0.63 KDM4E (0.42) HSP90AA1KDM4EALDH1A1POLBCCNA2
SCHEMBL24328657 0.63 KDM4E (0.42) HSP90AA1KDM4EALDH1A1POLBCCNA2
SCHEMBL13591831 0.62 KDM4E (0.49) HSP90AA1KDM4EALDH1A1POLBHTT
SCHEMBL10196368 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641805-B1 THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROTEIN KINASES CYCLACEL LTD (GB) 2010-01-13 EP disclosed
US-7576091-B2 Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases CYCLACEL LIMITED (GB) 2009-08-18 US disclosed
US-20060264628-A1 Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases CYCLACEL LIMITED (GB) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264628-A1 Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases CDK10, CSNK1A1L, CDK20 HSP90AA1 2394/4885KDM4E 3552/4885ALDH1A1 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.